My watch list  


Systematic (IUPAC) name
[3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16- (1-prop-2-enyl-2,3,4,5-tetrahydropyrrol- 1-yl)- 2,3,4,5,6,7,8,9,11,12,14,15,16,17- tetradecahydro-1H-cyclopenta[a] phenanthren- 17-yl] acetate
CAS number 119302-91-9
ATC code M03AC09
PubChem 441290
DrugBank APRD01221
Chemical data
Formula C32H53N2O4+
Mol. mass 529.774 g/mol
Pharmacokinetic data
Bioavailability NA
Protein binding ~30%
Metabolism some de-acetylation
Half life 66–80 minutes
Excretion Unchanged, in bile and urine
Therapeutic considerations
Pregnancy cat.


Legal status


Routes Intravenous

Rocuronium is an aminosteroid non-depolarizing (that is, it does not cause initial stimulation of muscles before weakening them) neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

It is a more recent member of a family of similar drugs. It has rapid onset, and intermediate duration of action. It is marketed under the trade name of Zemuron ® in the United States and Esmeron ® in most other countries.

There is considered to be some risk of allergic reaction to the drug in occasional patients, but, a similar incidence of allergic reactions has been observed by using other members of the drug class (non-depolarizing neuromuscular blocking drugs). The drug is commonly used in modern anaesthesia.

The γ-cyclodextrin derivative sugammadex has been recently introduced as a novel agent to reverse the action of rocuronium.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Rocuronium". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE